Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Intravitreal Injection of Aflibercept

Phase: N/A


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or ranibizumab -

External Links

Contact information

Primary Contact:

Theodore Leng, MD 650-723-6995

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: